Further analysis revealed that 360 lung adenocarcinoma cases with low expression of EZH2 had a median survival time of 119.87 months, compared to 357 cases with high expression of EZH2 (HR = 1.27, 95% CI 1.01−1.6, p < 0.05) (Fig. 5B). This evidence concerns the gene EZH2 and lung adenocarcinoma.